Relationships between pharmacokinetic and pharmacodynamic strategies for assessment of the risks for acute rejection and side effects of mofetil mycophenolate

Registry ID

EUCTR2005-006162-33

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

ROCHE

Start date

2006-05-19

Completion date

2008-09-09

Last update

2026-08-16

Conditions

• Kidney transplantation

Summary

To provide a preliminary evaluation of the correlation between the pharmacokinetic total MPA concentration at time 0 C0 , 40 min. C0.67 and 2 hours C2 ; free MPA concentration at time 0 C0,free , 40 min. C0.67,free and 2 hours C2,free and pharmacodynamic IMPDH II activity levels and IMPDH I and II gene expression parameters of MPA

Locations

• , , Italy

Related clinical trials

• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kidney transplantation / BEL-AMR

View on source registry